<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4759">
  <stage>Registered</stage>
  <submitdate>18/12/2014</submitdate>
  <approvaldate>18/12/2014</approvaldate>
  <nctid>NCT02324491</nctid>
  <trial_identification>
    <studytitle>An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes Mellitus</studytitle>
    <scientifictitle>Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of ZGN-440 (Subcutaneous Beloranib in Suspension) in Obese Subjects With Type 2 Diabetes Mellitus to Evaluate Weight Reduction, Glycemic Control, Safety, and Tolerability</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ZAF-203</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Obesity</healthcondition>
    <healthcondition>Type 2 Diabetes</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ZGN-440 for Injectable Suspension
Treatment: drugs - ZGN-440 Placebo for Injectable Suspension

Experimental: ZGN-440 Injectable Suspension (1.2mg) - ZGN-440 for Injectable Suspension

Experimental: ZGN-440 Injectable Suspension (1.8mg) - ZGN-440 for Injectable Suspension

Placebo Comparator: Placebo - ZGN-440 Placebo for Injectable Suspension


Treatment: drugs: ZGN-440 for Injectable Suspension
Subjects will receive ZGN-440 twice weekly subcutaneous injections for up to 52 weeks.

Treatment: drugs: ZGN-440 Placebo for Injectable Suspension
Subjects will receive placebo twice weekly subcutaneous injections for up to 52 weeks.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in body weight</outcome>
      <timepoint>Baseline to Week 26</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Safety and tolerability assessed by adverse events, laboratory evaluations, ECGs, vital signs, physical examinations</outcome>
      <timepoint>Baseline to Week 26 and Week 52</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in body weight</outcome>
      <timepoint>Baseline to Week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in fasting glycemic parameters - HbA1c, plasma glucose</outcome>
      <timepoint>Baseline to Week 26 and Week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in cardiometabolic parameters - Blood pressure, lipid concentrations, hs-CRP</outcome>
      <timepoint>Baseline to Week 26 and Week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Patient Reported Outcomes (PRO) scores</outcome>
      <timepoint>Baseline to Week 26 and Week 52</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Obese with BMI =30 kg/m2

          -  Type 2 diabetes mellitus

          -  HbA1c of 7-11%

          -  Fasting glucose &lt;15.5 mmol/L

          -  Treated with diet and exercise alone or with a stable regimen of metformin,
             sulfonylurea, pioglitazone, DPP-4 inhibitor, GLP-1 receptor agonist, SGLT-2 inhibitor
             or any combination of these agents

          -  Female subjects must be surgically sterile, post-menopausal or using long-acting
             contraception, which includes intrauterine devices or use of an implanted or
             injectable contraceptive</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Current or recent use of insulin

          -  Severe hypoglycemia within the prior 6 months

          -  Metabolic disorders or genetic disorders linked to obesity (e.g., Prader-Willi
             Syndrome)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>152</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC,WA</recruitmentstate>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <hospital>Pendlebury Research - Cardiff</hospital>
    <hospital>Australian Clinical Research Network - Maroubra</hospital>
    <hospital>Royal North Shore Hospital - St. Leonards</hospital>
    <hospital>Illawara Diabetes Service - Wollongong</hospital>
    <hospital>Q-Pharm - Herston</hospital>
    <hospital>Ipswich Research Institute - Ipswich</hospital>
    <hospital>AusTrials - Sherwood</hospital>
    <hospital>CMAX - Adelaide</hospital>
    <hospital>Box Hill Hospital - Box Hill</hospital>
    <hospital>St. Vincent's Hospital - Fitzroy</hospital>
    <hospital>Barwon Health - Geelong</hospital>
    <hospital>Austin Health - Heidelberg West</hospital>
    <hospital>Emeritus Research - Malvern East</hospital>
    <hospital>Baker IDI Heart and Diabetes Institute - Melbourne</hospital>
    <hospital>Keogh Institute for Medical Research - Nedlands</hospital>
    <postcode>2050 - Camperdown</postcode>
    <postcode>2285 - Cardiff</postcode>
    <postcode>2035 - Maroubra</postcode>
    <postcode>2065 - St. Leonards</postcode>
    <postcode>2500 - Wollongong</postcode>
    <postcode>4006 - Herston</postcode>
    <postcode>4305 - Ipswich</postcode>
    <postcode>4075 - Sherwood</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3128 - Box Hill</postcode>
    <postcode>3065 - Fitzroy</postcode>
    <postcode>3220 - Geelong</postcode>
    <postcode>3081 - Heidelberg West</postcode>
    <postcode>3145 - Malvern East</postcode>
    <postcode>3004 - Melbourne</postcode>
    <postcode>6009 - Nedlands</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Zafgen, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate efficacy and safety of ZGN-440 (beloranib) in obese
      adult subjects with type 2 diabetes mellitus.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02324491</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dennis Kim, MD</name>
      <address>Zafgen, Inc.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>